JP2024538141A5 - - Google Patents

Info

Publication number
JP2024538141A5
JP2024538141A5 JP2024522609A JP2024522609A JP2024538141A5 JP 2024538141 A5 JP2024538141 A5 JP 2024538141A5 JP 2024522609 A JP2024522609 A JP 2024522609A JP 2024522609 A JP2024522609 A JP 2024522609A JP 2024538141 A5 JP2024538141 A5 JP 2024538141A5
Authority
JP
Japan
Prior art keywords
domain
polypeptide
activatable
polypeptide complex
bispecific polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078160 external-priority patent/WO2023064929A1/en
Publication of JP2024538141A publication Critical patent/JP2024538141A/ja
Publication of JP2024538141A5 publication Critical patent/JP2024538141A5/ja
Pending legal-status Critical Current

Links

JP2024522609A 2021-10-15 2022-10-14 活性化可能なポリペプチド複合体 Pending JP2024538141A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256417P 2021-10-15 2021-10-15
US63/256,417 2021-10-15
US202263370897P 2022-08-09 2022-08-09
US63/370,897 2022-08-09
PCT/US2022/078160 WO2023064929A1 (en) 2021-10-15 2022-10-14 Activatable polypeptide complex

Publications (2)

Publication Number Publication Date
JP2024538141A JP2024538141A (ja) 2024-10-18
JP2024538141A5 true JP2024538141A5 (cg-RX-API-DMAC7.html) 2025-10-21

Family

ID=84330396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522609A Pending JP2024538141A (ja) 2021-10-15 2022-10-14 活性化可能なポリペプチド複合体

Country Status (11)

Country Link
US (1) US20230174995A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416178A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538141A (cg-RX-API-DMAC7.html)
KR (1) KR20240118749A (cg-RX-API-DMAC7.html)
AU (1) AU2022367525A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235018A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001178A1 (cg-RX-API-DMAC7.html)
IL (1) IL312143A (cg-RX-API-DMAC7.html)
MX (1) MX2024004564A (cg-RX-API-DMAC7.html)
TW (1) TW202323282A (cg-RX-API-DMAC7.html)
WO (1) WO2023064929A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2025240659A2 (en) * 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof
WO2026067689A1 (zh) * 2024-09-28 2026-04-02 浙江道尔生物科技有限公司 肿瘤特异性激活的蛋白药物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
SG11201408554QA (en) 2012-06-22 2015-02-27 Cytomx Therapeutics Inc Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
EP2882844B1 (en) 2012-08-10 2018-10-03 Cytomx Therapeutics Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
BR112017023872A2 (pt) 2015-05-04 2018-07-24 Cytomx Therapeutics Inc anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
AU2016258988A1 (en) 2015-05-04 2017-12-07 Cytomx Therapeutics, Inc Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
TWI787796B (zh) 2015-05-04 2022-12-21 美商Cytomx生物製藥公司 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
WO2019077092A1 (en) * 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
JP7729778B2 (ja) * 2019-03-28 2025-08-26 オリオニス バイオサイエンシズ,インコーポレイテッド Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体

Similar Documents

Publication Publication Date Title
JP2022065174A5 (cg-RX-API-DMAC7.html)
JP2024539650A5 (cg-RX-API-DMAC7.html)
CN1294148C (zh) 环状单链三特异抗体
CN1195779C (zh) 抗人卵巢癌抗人cd3双特异性抗体
JP2022064924A5 (cg-RX-API-DMAC7.html)
JP2022536898A5 (cg-RX-API-DMAC7.html)
JP2023506750A5 (cg-RX-API-DMAC7.html)
JP2021524269A5 (cg-RX-API-DMAC7.html)
JP2023178323A5 (cg-RX-API-DMAC7.html)
JP2023520922A5 (cg-RX-API-DMAC7.html)
JP2022551081A5 (cg-RX-API-DMAC7.html)
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
JP2021524275A5 (cg-RX-API-DMAC7.html)
JP2020516287A5 (cg-RX-API-DMAC7.html)
JP2025504909A5 (cg-RX-API-DMAC7.html)
US12583941B2 (en) Fibroblast activation protein binding agents and use thereof
CN1186445C (zh) 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用
JP2021524270A5 (cg-RX-API-DMAC7.html)
JP2025160226A5 (cg-RX-API-DMAC7.html)
JP2023511376A5 (cg-RX-API-DMAC7.html)
JP2025512865A5 (cg-RX-API-DMAC7.html)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2023538366A5 (cg-RX-API-DMAC7.html)
JP2024528935A5 (cg-RX-API-DMAC7.html)
JPWO2022102768A5 (cg-RX-API-DMAC7.html)